Skip to main content

Advertisement

SpringerLink
Log in

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

  • NON-THEMATIC REVIEW
  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Radiosensitivity varies to a great extent across tumor types and also between patients bearing the same type of tumor. Radiation oncology pioneered the field of biomarkers with attempts to correlate tumor response to clonogenic survival, tumor potential doubling time (Tpot), and PaO2. Biomarkers predicting the clinical outcome after radiotherapy are already available, but their levels of evidence are heterogeneous. In light of these molecular factors, the issue of personalized radiation therapy in combination or as a standalone modality is addressed. Known molecular prognostic and predictive biomarkers and their present or potential respective therapeutic implications are described for six tumor types where radiotherapy is considered to be part of the mainstay: chemoradiation (e.g., gliomas, head and neck, cervical cancer), radiotherapy with or without androgen deprivation (e.g., prostate), neo-adjuvant chemoradiation (e.g., rectum), or adjuvant radiotherapy (e.g., breast).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Jr., Kemeny, N. E., Jessup, J. M., et al. (1996). Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute, 88(20), 1456–1466.

    PubMed  CAS  Google Scholar 

  2. Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., De Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine, 352(10), 997–1003.

    PubMed  CAS  Google Scholar 

  3. Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., et al. (2010). MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-Oncology, 12(2), 116–121.

    PubMed  CAS  Google Scholar 

  4. Gerstner, E. R., Yip, S., Wang, D. L., Louis, D. N., Iafrate, A. J., & Batchelor, T. T. (2009). Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology, 73(18), 1509–1510.

    PubMed  CAS  Google Scholar 

  5. Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., et al. (2008). MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(13), 2192–2197.

    Google Scholar 

  6. Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., et al. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(35), 5874–5880.

    CAS  Google Scholar 

  7. Cairncross, G., & Jenkins, R. (2008). Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer journal (Sudbury, Mass.), 14(6), 352–357.

    Google Scholar 

  8. Bauman, G. S., Ino, Y., Ueki, K., Zlatescu, M. C., Fisher, B. J., Macdonald, D. R., et al. (2000). Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. International journal of radiation oncology, biology, physics, 48(3), 825–830.

    PubMed  CAS  Google Scholar 

  9. Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., et al. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 24(18), 2707–2714.

    CAS  Google Scholar 

  10. Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine, 360(8), 765–773.

    PubMed  CAS  Google Scholar 

  11. Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., et al. (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(34), 5743–5750.

    CAS  Google Scholar 

  12. Yip, S., Iafrate, A. J., & Louis, D. N. (2008). Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers. Journal of Neuropathology and Experimental Neurology, 67(1), 1–15.

    PubMed  CAS  Google Scholar 

  13. Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., et al. (2003). Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Research, 63(20), 6962–6970.

    PubMed  CAS  Google Scholar 

  14. Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., et al. (2008). Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(18), 3015–3024.

    CAS  Google Scholar 

  15. Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., et al. (2008). Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(34), 5603–5609.

    CAS  Google Scholar 

  16. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., & Dewhirst, M. W. (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 38(2), 285–289.

    PubMed  CAS  Google Scholar 

  17. Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., et al. (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 77(1), 18–24.

    Google Scholar 

  18. Bussink, J., Kaanders, J. H. A. M., & Van der Kogel, A. J. (2003). Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 67(1), 3–15.

    Google Scholar 

  19. De Schutter, H., Landuyt, W., Verbeken, E., Goethals, L., Hermans, R., & Nuyts, S. (2005). The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/− chemotherapy. BMC Cancer, 5, 42.

    PubMed  Google Scholar 

  20. Gee, H. E., Camps, C., Buffa, F. M., Patiar, S., Winter, S. C., Betts, G., et al. (2010). hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 116(9), 2148–2158.

    PubMed  Google Scholar 

  21. Calvin, D. P., Hammond, M. E., Pajak, T. F., Trotti, A. M., Meredith, R. F., Rotman, M., et al. (2007). Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90–03 Trial. American Journal of Clinical Oncology, 30(4), 406–419.

    PubMed  Google Scholar 

  22. Overgaard, J., Eriksen, J. G., Nordsmark, M., Alsner, J., & Horsman, M. R. (2005). Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. The Lancet Oncology, 6(10), 757–764.

    PubMed  CAS  Google Scholar 

  23. Hoff, C. M., Hansen, H. S., Overgaard, M., Grau, C., Johansen, J., Bentzen, J., et al. (2011). The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy—results from the randomized DAHANCA 5 study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 98(1), 28–33.

    Google Scholar 

  24. Lim, A. M., Rischin, D., Fisher, R., Cao, H., Kwok, K., Truong, D., et al. (2012). Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clinical cancer research: an official journal of the American Association for Cancer Research, 18(1), 301–307.

    CAS  Google Scholar 

  25. Gillison, M. L., D’Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., et al. (2008). Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. Journal of the National Cancer Institute, 100(6), 407–420.

    PubMed  Google Scholar 

  26. Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., et al. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. The New England Journal of Medicine, 363(1), 24–35.

    PubMed  CAS  Google Scholar 

  27. Ragin, C. C. R., & Taioli, E. (2007). Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. International journal of cancer. Journal international du cancer, 121(8), 1813–1820.

    PubMed  CAS  Google Scholar 

  28. Lassen, P., Eriksen, J. G., Hamilton-Dutoit, S., Tramm, T., Alsner, J., & Overgaard, J. (2009). Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(12), 1992–1998.

    CAS  Google Scholar 

  29. Rischin, D., Young, R. J., Fisher, R., Fox, S. B., Le, Q.-T., Peters, L. J., et al. (2010). Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 28(27), 4142–4148.

    CAS  Google Scholar 

  30. Grandis, J. R., & Tweardy, D. J. (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Research, 53(15), 3579–3584.

    PubMed  CAS  Google Scholar 

  31. Chung, C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., et al. (2006). Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 24(25), 4170–4176.

    CAS  Google Scholar 

  32. Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M. E., Cadoni, G., et al. (1996). Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. British Journal of Cancer, 74(8), 1253–1257.

    PubMed  CAS  Google Scholar 

  33. Bentzen, S. M., Atasoy, B. M., Daley, F. M., Dische, S., Richman, P. I., Saunders, M. I., et al. (2005). Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(24), 5560–5567.

    CAS  Google Scholar 

  34. Ang, K. K., Berkey, B. A., Tu, X., Zhang, H.-Z., Katz, R., Hammond, E. H., et al. (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research, 62(24), 7350–7356.

    PubMed  CAS  Google Scholar 

  35. Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 354(6), 567–578.

    PubMed  CAS  Google Scholar 

  36. Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., et al. (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology, 11(1), 21–28.

    PubMed  CAS  Google Scholar 

  37. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., et al. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366(9503), 2087–2106.

    PubMed  CAS  Google Scholar 

  38. Bartelink, H., Horiot, J.-C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., et al. (2007). Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 25(22), 3259–3265.

    Google Scholar 

  39. Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., et al. (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(14), 2373–2378.

    Google Scholar 

  40. Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010). Breast cancer subtypes and the risk of local and regional relapse. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 28(10), 1684–1691.

    Google Scholar 

  41. Paulsen, G. H., Strickert, T., Marthinsen, A. B., & Lundgren, S. (1996). Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta oncologica (Stockholm, Sweden), 35(8), 1011–1019.

    CAS  Google Scholar 

  42. Harris, E. E. R., Christensen, V. J., Hwang, W.-T., Fox, K., & Solin, L. J. (2005). Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(1), 11–16.

    CAS  Google Scholar 

  43. Pierce, L. J., Hutchins, L. F., Green, S. R., Lew, D. L., Gralow, J. R., Livingston, R. B., et al. (2005). Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(1), 24–29.

    CAS  Google Scholar 

  44. Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999). Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research, 59(6), 1347–1355.

    PubMed  CAS  Google Scholar 

  45. Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., et al. (2009). Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG Phase III Trial N9831. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(16), 2638–2644.

    CAS  Google Scholar 

  46. De Azambuja, E., Cardoso, F., De Castro, G., Jr., Colozza, M., Mano, M. S., Durbecq, V., et al. (2007). Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. British Journal of Cancer, 96(10), 1504–1513.

    PubMed  Google Scholar 

  47. Elkhuizen, P. H., Voogd, A. C., Van den Broek, L. C., Tan, I. T., Van Houwelingen, H. C., Leer, J. W., et al. (1999). Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case–control study of histological factors and alterations in oncogene expression. International journal of radiation oncology, biology, and physics, 45(1), 73–83.

    CAS  Google Scholar 

  48. Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., et al. (2006). Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 24(16), 2437–2443.

    Google Scholar 

  49. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917–921.

    PubMed  CAS  Google Scholar 

  50. Chang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., et al. (2005). Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America, 102(10), 3738–3743.

    PubMed  CAS  Google Scholar 

  51. Van de Vijver, M. J., He, Y. D., Van’t Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. The New England Journal of Medicine, 347(25), 1999–2009.

    PubMed  Google Scholar 

  52. Chi, J.-T., Wang, Z., Nuyten, D. S. A., Rodriguez, E. H., Schaner, M. E., Salim, A., et al. (2006). Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Medicine, 3(3), e47.

    PubMed  Google Scholar 

  53. Nuyten, D. S. A., Kreike, B., Hart, A. A. M., Chi, J.-T. A., Sneddon, J. B., Wessels, L. F. A., et al. (2006). Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast cancer research: BCR, 8(5), R62.

    PubMed  Google Scholar 

  54. Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., et al. (2010). Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 28(10), 1677–1683.

    Google Scholar 

  55. Kreike, B., Halfwerk, H., Armstrong, N., Bult, P., Foekens, J. A., Veltkamp, S. C., et al. (2009). Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(12), 4181–4190.

    CAS  Google Scholar 

  56. Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Jr., Yossepowitch, O., Vickers, A. J., et al. (2009). Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(26), 4300–4305.

    Google Scholar 

  57. Zelefsky, M. J., Kattan, M. W., Fearn, P., Fearon, B. L., Stasi, J. P., Shippy, A. M., et al. (2007). Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology, 70(2), 283–287.

    PubMed  Google Scholar 

  58. Roach, M., 3rd, Waldman, F., & Pollack, A. (2009). Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer, 115(13 Suppl), 3112–3120.

    PubMed  Google Scholar 

  59. Roach, M., 3rd, Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., et al. (2008). Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(4), 585–591.

    Google Scholar 

  60. Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A., Grignon, D. J., Brereton, H. D., et al. (2008). Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(15), 2497–2504.

    CAS  Google Scholar 

  61. Hanks, G. E., Hanlon, A. L., Pinover, W. H., Horwitz, E. M., Price, R. A., & Schultheiss, T. (2000). Dose selection for prostate cancer patients based on dose comparison and dose response studies. International journal of radiation oncology, biology, physics, 46(4), 823–832.

    PubMed  CAS  Google Scholar 

  62. Pollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., Von Eschenbach, A. C., Antolak, J. A., et al. (2000). Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 18(23), 3904–3911.

    CAS  Google Scholar 

  63. Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., et al. (2008). Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International journal of radiation oncology, biology, physics, 70(1), 67–74.

    PubMed  Google Scholar 

  64. Grignon, D. J., Caplan, R., Sarkar, F. H., Lawton, C. A., Hammond, E. H., Pilepich, M. V., et al. (1997). p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. Journal of the National Cancer Institute, 89(2), 158–165.

    PubMed  CAS  Google Scholar 

  65. Che, M., DeSilvio, M., Pollack, A., Grignon, D. J., Venkatesan, V. M., Hanks, G. E., et al. (2007). Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. International journal of radiation oncology, biology, physics, 69(4), 1117–1123.

    PubMed  CAS  Google Scholar 

  66. Khor, L. Y., Moughan, J., Al-Saleem, T., Hammond, E. H., Venkatesan, V., Rosenthal, S. A., et al. (2007). Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92–02. Clinical cancer research: an official journal of the American Association for Cancer Research, 13(12), 3585–3590.

    CAS  Google Scholar 

  67. Vergis, R., Corbishley, C. M., Thomas, K., Horwich, A., Huddart, R., Khoo, V., et al. (2010). Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. International journal of radiation oncology, biology, Physics, 78(1), 35–41.

    PubMed  CAS  Google Scholar 

  68. Khor, L.-Y., Bae, K., Paulus, R., Al-Saleem, T., Hammond, M. E., Grignon, D. J., et al. (2009). MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92–02. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(19), 3177–3184.

    Google Scholar 

  69. Zhang, M., Ho, A., Hammond, E. H., Suzuki, Y., Bermudez, R. S., Lee, R. J., et al. (2009). Prognostic value of survivin in locally advanced prostate cancer: Study based on RTOG 8610. International journal of radiation oncology, biology, physics, 73(4), 1033–1042.

    PubMed  CAS  Google Scholar 

  70. Chakravarti, A., Heydon, K., Wu, C. L., Hammond, E., Pollack, A., Roach, M., et al. (2003). Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 86–10. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 21(17), 3328–3334.

    CAS  Google Scholar 

  71. Chakravarti, A., DeSilvio, M., Zhang, M., Grignon, D., Rosenthal, S., Asbell, S. O., et al. (2007). Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 25(21), 3082–3089.

    Google Scholar 

  72. Li, R., Heydon, K., Hammond, M. E., Grignon, D. J., Roach, M., 3rd, Wolkov, H. B., et al. (2004). Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in radiation therapy oncology group protocol 86–10. Clinical cancer research: an official journal of the American Association for Cancer Research, 10(12 Pt 1), 4118–4124.

    CAS  Google Scholar 

  73. Pollack, A., DeSilvio, M., Khor, L.-Y., Li, R., Al-Saleem, T. I., Hammond, M. E., et al. (2004). Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92–02. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 22(11), 2133–2140.

    CAS  Google Scholar 

  74. Khor, L.-Y., Bae, K., Pollack, A., Hammond, M. E. H., Grignon, D. J., Venkatesan, V. M., et al. (2007). COX-2 expression predicts prostate-cancer outcome: Analysis of data from the RTOG 92–02 trial. The Lancet Oncology, 8(10), 912–920.

    PubMed  CAS  Google Scholar 

  75. Khor, L.-Y., Bae, K., Al-Saleem, T., Hammond, E. H., Grignon, D. J., Sause, W. T., et al. (2008). Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86–10. International Journal of radiation oncology, biology, physics, 71(5), 1309–1315.

    PubMed  CAS  Google Scholar 

  76. Pollack, A., Bae, K., Khor, L.-Y., Al-Saleem, T., Hammond, M. E., Venkatesan, V., et al. (2009). The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92–02. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(17), 5478–5484.

    CAS  Google Scholar 

  77. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: Individual patient data meta-analysis. (2010). Cochrane database of systematic reviews (Online), (1), CD008285.

  78. Bachtiary, B., Schindl, M., Pötter, R., Dreier, B., Knocke, T. H., Hainfellner, J. A., et al. (2003). Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 9(6), 2234–2240.

    CAS  Google Scholar 

  79. Burri, P., Djonov, V., Aebersold, D. M., Lindel, K., Studer, U., Altermatt, H. J., et al. (2003). Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. International journal of radiation oncology, biology, physics, 56(2), 494–501.

    PubMed  CAS  Google Scholar 

  80. Rischin, D., Narayan, K., Oza, A. M., Mileshkin, L., Bernshaw, D., Choi, J., et al. (2010). Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 20(5), 827–833.

    Google Scholar 

  81. Harima, Y., Sawada, S., Nagata, K., Sougawa, M., & Ohnishi, T. (2002). Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. International journal of radiation oncology, biology, physics, 52(5), 1345–1351.

    PubMed  CAS  Google Scholar 

  82. Bachtiary, B., Obermair, A., Dreier, B., Birner, P., Breitenecker, G., Knocke, T.-H., et al. (2002). Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. International journal of cancer. Journal international du cancer, 102(3), 237–243.

    PubMed  CAS  Google Scholar 

  83. Ishikawa, H., Mitsuhashi, N., Sakurai, H., Maebayashi, K., & Niibe, H. (2001). The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer, 91(1), 80–89.

    PubMed  CAS  Google Scholar 

  84. Kim, J.-Y., Park, S., Nam, B.-H., Roh, J.-W., Lee, C. H., Kim, Y.-H., et al. (2009). Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27(30), 5088–5093.

    Google Scholar 

  85. Loncaster, J. A., Cooper, R. A., Logue, J. P., Davidson, S. E., Hunter, R. D., & West, C. M. (2000). Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. British Journal of Cancer, 83(5), 620–625.

    PubMed  CAS  Google Scholar 

  86. Noordhuis, M. G., Eijsink, J. J. H., Ten Hoor, K. A., Roossink, F., Hollema, H., Arts, H. J. G., et al. (2009). Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(23), 7389–7397.

    CAS  Google Scholar 

  87. Kim, G. E., Kim, Y. B., Cho, N. H., Chung, H.-C., Pyo, H. R., Lee, J. D., et al. (2004). Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clinical cancer research: an official journal of the American Association for Cancer Research, 10(4), 1366–1374.

    CAS  Google Scholar 

  88. Wong, Y. F., Selvanayagam, Z. E., Wei, N., Porter, J., Vittal, R., Hu, R., et al. (2003). Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clinical cancer research: an official journal of the American Association for Cancer Research, 9(15), 5486–5492.

    CAS  Google Scholar 

  89. Weidhaas, J. B., Li, S.-X., Winter, K., Ryu, J., Jhingran, A., Miller, B., et al. (2009). Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(12), 4199–4206.

    CAS  Google Scholar 

  90. Heald, R. J., & Ryall, R. D. (1986). Recurrence and survival after total mesorectal excision for rectal cancer. Lancet, 1(8496), 1479–1482.

    PubMed  CAS  Google Scholar 

  91. Van Gijn, W., Marijnen, C. A. M., Nagtegaal, I. D., Kranenbarg, E. M.-K., Putter, H., Wiggers, T., et al. (2011). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. The Lancet Oncology, 12(6), 575–582.

    PubMed  Google Scholar 

  92. Braendengen, M., Tveit, K. M., Berglund, A., Birkemeyer, E., Frykholm, G., Påhlman, L., et al. (2008). Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(22), 3687–3694.

    CAS  Google Scholar 

  93. Giralt, J., De las Heras, M., Cerezo, L., Eraso, A., Hermosilla, E., Velez, D., et al. (2005). The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 74(2), 101–108.

    CAS  Google Scholar 

  94. Kim, J.-S., Kim, J.-M., Li, S., Yoon, W.-H., Song, K.-S., Kim, K.-H., et al. (2006). Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. International journal of radiation oncology, biology, physics, 66(1), 195–200.

    PubMed  Google Scholar 

  95. Spindler, K.-L. G., Nielsen, J. N., Lindebjerg, J., Brandslund, I., & Jakobsen, A. (2006). Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. International journal of radiation oncology, biology, physics, 66(2), 500–504.

    PubMed  Google Scholar 

  96. Machiels, J.-P., Sempoux, C., Scalliet, P., Coche, J.-C., Humblet, Y., Van Cutsem, E., et al. (2007). Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 18(4), 738–744.

    Google Scholar 

  97. Bengala, C., Bettelli, S., Bertolini, F., Salvi, S., Chiara, S., Sonaglio, C., et al. (2009). Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 20(3), 469–474.

    CAS  Google Scholar 

  98. Erben, P., Ströbel, P., Horisberger, K., Popa, J., Bohn, B., Hanfstein, B., et al. (2011). KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. International journal of radiation oncology, biology, physics, 81(4), 1032–1038.

    PubMed  CAS  Google Scholar 

  99. He, Y., Van’t Veer, L. J., Mikolajewska-Hanclich, I., Van Velthuysen, M.-L. F., Zeestraten, E. C. M., Nagtegaal, I. D., et al. (2009). PIK3CA mutations predict local recurrences in rectal cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(22), 6956–6962.

    CAS  Google Scholar 

  100. Saw, R. P. M., Morgan, M., Koorey, D., Painter, D., Findlay, M., Stevens, G., et al. (2003). p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Diseases of the colon and rectum, 46(2), 192–202.

    PubMed  Google Scholar 

  101. Negri, F. V., Campanini, N., Camisa, R., Pucci, F., Bui, S., Ceccon, G., et al. (2008). Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. British Journal of Cancer, 98(1), 143–147.

    PubMed  CAS  Google Scholar 

  102. Terrazzino, S., Agostini, M., Pucciarelli, S., Pasetto, L. M., Friso, M. L., Ambrosi, A., et al. (2006). A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenetics and Genomics, 16(11), 817–824.

    PubMed  CAS  Google Scholar 

  103. Ghadimi, B. M., Grade, M., Difilippantonio, M. J., Varma, S., Simon, R., Montagna, C., et al. (2005). Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(9), 1826–1838.

    CAS  Google Scholar 

  104. Watanabe, T., Komuro, Y., Kiyomatsu, T., Kanazawa, T., Kazama, Y., Tanaka, J., et al. (2006). Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Research, 66(7), 3370–3374.

    PubMed  CAS  Google Scholar 

  105. Garcia-Aguilar, J., Chen, Z., Smith, D. D., Li, W., Madoff, R. D., Cataldo, P., et al. (2011). Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Annals of Surgery, 254(3), 486–492. discussion 492–493.

    PubMed  Google Scholar 

  106. Chargari, C., Soria, J.-C., & Deutsch, E. (2013). Controversies and challenges regarding the impact of radiation therapy on survival. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO, 24(1), 38–46.

    CAS  Google Scholar 

Download references

Conflicts of interest

The authors declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Molecular Radiotherapy Laboratory, INSERM 1030, Faculté de médecine du Kremlin Bicêtre, Université Paris Sud XI, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France

    Jean-Emmanuel Bibault, Ingrid Fumagalli, Cyrus Chargari & Eric Deutsch

  2. Early Drug Development Unit (SITEP), Department of Medicine, Institut Gustave Roussy, Faculté de medicine du Kremlin Bicêtre, Université Paris Sud XI, 114 rue Edouard Vaillant, 94805, Villejuif, France

    Charles Ferté, Jean-Charles Soria & Eric Deutsch

  3. Radiation Oncology, Hôpital d’Instruction des Armées du Val-de-Grâce, 74 Boulevard de Port Royal, 75005, Paris, France

    Cyrus Chargari

Authors
  1. Jean-Emmanuel Bibault
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingrid Fumagalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Ferté
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cyrus Chargari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Charles Soria
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric Deutsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Deutsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bibault, JE., Fumagalli, I., Ferté, C. et al. Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer Metastasis Rev 32, 479–492 (2013). https://doi.org/10.1007/s10555-013-9419-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-013-9419-7

Keywords

Search

Navigation